CPA
IDXG

Cowen Prime Advisors’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Cowen Prime Advisors’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-140
Closed -$1K – 193
2018
Q4 		$1K Buy
+140
New +$1.68K ﹤0.01% 183
2018
Q3 		– Sell
-240
Closed -$2K – 221
2018
Q2 		$2K Buy
+240
New +$2.13K ﹤0.01% 198

Other funds holding IDXG

PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Cowen Prime Advisors's IDXG Position: Q1 2019 in Review

Cowen Prime Advisors sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2019, closing a stake of 140 shares — an estimated $1K sold.

Cowen Prime Advisors first reported a position in IDXG in Q2 2018 and held it in 2 quarters. The position peaked at $2K in Q2 2018. 20 funds tracked by Wall St. Rank hold IDXG as of Q1 2019.

  • Cowen Prime Advisors reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Cowen Prime Advisors sold 140 Interpace Biosciences, Inc. Common Stock shares in Q1 2019, an estimated $1K.
  • Cowen Prime Advisors first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Cowen Prime Advisors's Interpace Biosciences, Inc. Common Stock position peaked at $2K in Q2 2018.
  • 20 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2019.

Based on Cowen Prime Advisors's 13F filing for Q1 2019, filed 29 Apr 2019.